CHF Solutions Becomes Nuwellis Inc.

In order to reflect the evolution of its brand, CHF Solutions – a leader in the heart failure space – has changed its name to Nuwellis Inc. to reflect its core therapeutic focus areas: pediatric, critical care, and heart failure fluid imbalance.
 
Historically, the company’s Aquadex SmartFlow System was used to remove excess fluid in patients suffering from heart failure, helping to alleviate the burden that fluid overload has on vital organs and subsequently reducing the need for hospitalization.¹ However, the benefits of Aquadex don’t stop with heart failure. The product is clinically proven to improve outcomes in critical care and pediatric patients weighing 20 kg or more.^1,2
 
Nuwellis reflects the “new well” that signifies better tomorrows for patients, their families and their providers. Each can experience the transformation of care made possible by the company’s fluid management technology.
 
About Aquadex
Aquadex is a smart fluid management platform that uses ultrafiltration to restore fluid balance in patients experiencing fluid overload. In February 2020, the company received 510(k) clearance for its technology to be used in pediatric patients weighing 20 kg or more. Medical facilities across the globe expressed an interest in the pediatric therapy option, as it addresses a large unmet need in the treatment of children. Another common use of Aquadex occurs in critically-ill patients suffering from trauma, burns, severe Covid-19 and acute kidney injury.  
 
“2020 was a transformational year for our company, we grew in unexpected ways and expanded our therapeutic focus areas,” said Nestor Jaramillo, Jr., president and CEO of Nuwellis. “We are no longer exclusively a heart failure company, as our prior name suggested. Nuwellis represents our mission to better adhere to the needs of all patients suffering from fluid imbalance and reflects our new commercial focus. This is an exciting time for our company and represents the growth we have seen and strive to continue to achieve. We will continue to evolve in order to give patients and their providers the best technology to restore fluid balance, and rebranding is a high-level change that reflects our commitment.”
 
In conjunction with the name change, the company’s ticker symbol listed on the NASDAQ will change from CHFS to NUWE, effective April 27, 2021, and the CUSIP numbers for its common stock and Series F Convertible Preferred stock will change to 67113Y 108 and 67113Y 207, respectively. The company’s outstanding warrants expiring on November 20, 2024, March 12, 2024, January 28, 2025 and August 21, 2025 will change to 67113Y 116, 67113Y 124, 67113Y 132 and 67113Y 140, respectively.
 
The company’s official website will be changed to www.nuwellis.com, effective immediately.
 
References:
¹ Siddiqui WJ, et al. Heart Fail Rev. 2017 Nov;22(6):685-698. 
² Ronco C, et al. Proc (Bayl Univ Med Cent). 2020 Apr 16;0(0):1-6.